nnz-2591 compared to pbt

PBT has a valuation of around 50m with around 5m cash , surely we can place a valuation of 10-15m on NNZ-2591 which has shown exciting pre-clinical results. The only reason its been left behind was other priorities such as NNZ-2566 , its another reason to be overweight this stock.

From 2012 AGM

http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=299573

NNZ-2591 is the lead molecule in Neuren’s diketopiperazine or DKP portfolio. DKPs are dipeptides (as opposed to tripeptides like NNZ-2566) and NNZ-2591 comprises two of the three peptides that make up NNZ-2566. NNZ-2591 is 100% orally available and, from the initial tests we’ve performed, seems to be very safe.

It is an extremely promising molecule with strong in vivo results in Parkinson’s disease, stroke, cognitive impairment and peripheral neuropathy. At this point, it appears to be a very good candidate for chronic oral administration in a range of neurological conditions.

We have committed limited resources to NNZ-2591 to develop a reliable manufacturing process and, as we did with the US Army for NNZ-2566, to elucidate the mechanism of action. These initial steps will inform our future decisions about which indications to pursue and how to position the molecule with respect to commercialization.

http://www.femail.com.au/memory-loss-drug-parkinsons-alzheimers.htm

New drug to reverse memory loss from Parkinson's and Alzheimer's disease

Neuren Pharmaceuticals today announced exciting preclinical results of its drug, NNZ -2591, which has shown an improvement in learning and memory after oral dosing. The results suggest that NNZ-2591 has the capacity to improve learning and memory processes after short-term treatment.

The new data extends the potential application of NNZ-2591 as a treatment for dementias such as those associated with Parkinson's and Alzheimer's disease.

Improvements were observed as early as two days after initial treatment and were observed throughout the four day study. NNZ-2591 was administered as an oral dose to the animals in each test, further supporting the development of this drug as an oral treatment for chronic disorders.

Previous studies have shown that NNZ-2591 is effective at improving the motor skills impairment seen in an experimental model of Parkinson's disease and also showed that the drug produced a long-term benefit in this model of the disease, rather than just temporary symptomatic relief.